MSANTD1: A Potential Drug Target and Biomarker (G345222)

Target Name: MSANTD1

NCBI ID: G345222

MSANTD1

MSANTD1: A Potential Drug Target and Biomarker

Myb/SANT-like DNA-binding domain-containing protein 1 (MSANTD1) is a protein that is expressed in various tissues and cells in the human body. It is characterized by the presence of a Myb domain, a SANT-like domain, and a unique N-terminus. MSANTD1 has been shown to play a critical role in various cellular processes, including DNA replication, transcription, and repair. In addition, MSANTD1 has also been shown to be involved in the regulation of cell adhesion, migration, and the response to environmental stimuli.

The MSANTD1 gene has been identified and its function has been extensively studied. The protein encoded by this gene is approximately 14 kDa and has been shown to have various functions in the cell. One of the most significant functions of MSANTD1 is its ability to bind to specific DNA sequences. This is accomplished through the use of a SANT-like domain, which is known for its ability to form a stable complex with DNA. In addition, MSANTD1 also has the ability to interact with other proteins, including the protein encoded by the CDK2 gene.

The MSANTD1 gene has been shown to be involved in various cellular processes, including cell growth, cell adhesion, and cell cycle regulation. In addition, MSANTD1 has also been shown to play a critical role in the regulation of cell survival and the response to environmental stimuli.

Drug Targeting

Drug targeting is a process that involves the use of small molecules or antibodies to selectively bind to a specific protein and alter its function. In the case of MSANTD1, drug targeting could potentially be used as a means of treating various diseases and conditions.

One potential drug that may target MSANTD1 is currently in clinical trials for the treatment of various cancers, including breast, ovarian, and colorectal cancers. This drug works by inhibiting the activity of MSANTD1, leading to the inhibition of cell growth and the regression of cancerous tumors.

Another potential drug that may target MSANTD1 is currently being investigated for the treatment of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. This drug is being tested for its ability to treat these conditions by inhibiting the activity of MSANTD1 and its downstream targets.

Biomarker

MSANTD1 has also been shown to be involved in the regulation of various cellular processes, making it an attractive candidate for use as a biomarker. For example, MSANTD1 has been shown to play a critical role in the regulation of cell adhesion and cell migration. In addition, MSANTD1 has also been shown to play a role in the regulation of cell cycle progression and the response to environmental stimuli.

One potential way to use MSANTD1 as a biomarker is through the use of techniques such as qRT-PCR and western blotting. These techniques can be used to measure the expression and activity of MSANTD1 in various cellular samples, including patient tissue samples, cell culture samples, and experimental models of disease.

Conclusion

MSANTD1 is a protein that has been shown to play a critical role in various cellular processes in the human body. Its unique SANT-like domain and ability to bind to specific DNA sequences make it an attractive candidate for use as a drug target or biomarker. Further research is needed to fully understand the functions of MSANTD1 and its potential as a drug target or biomarker.

Protein Name: Myb/SANT DNA Binding Domain Containing 1

The "MSANTD1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MSANTD1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets